Other
Allogeneic Stem Cell Transplantation
1
Pipeline Programs↗
13
Active Trials↗
2
Companies Involved↗
Allogeneic Stem Cell Transplantation is an early-stage landscape with 1 program across 2 companies. The most active players are Gilead, Novo Nordisk. 1 program is in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical
No programs
Phase 1
No programs
Phase 2
No programs
Approved
No programs
Analysis
Trial Status
82
clinical trials
Completed40 · 49%
Unknown status15 · 18%
Terminated9 · 11%
Recruiting6 · 7%
Withdrawn4 · 5%
Active, not recruiting4 · 5%
Other4 · 5%
Clinical Trials
Trial Activity
82 trials
Allogeneic Stem Cell Transplantation for Children and Adolescents With Acute Lymphoblastic Leukaemia
Recruiting·—·Phase 2/3·NCT01949129·1,800 enrolled
Vitamin A Supplementation in Allogeneic Stem Cell Transplantation.
Recruiting·—·Phase 2·NCT06450925·190 enrolled
Base Edited CAR T Cells Against AML: Deep Conditioning Ahead of Allogeneic Stem Cell Transplantation
Active, not recruiting·GGreat Ormond Street Hospital for Children NHS Foundation Trust·Phase 1·NCT05942599·10 enrolled
CD34+ (Non-Malignant) Stem Cell Selection for Patients Receiving Allogeneic Stem Cell Transplantation
Active, not recruiting·—·Phase 1/2·NCT01966367·37 enrolled
Evaluation of Fibrotic Disease Activity in Cardiopulmonary Disorders Using 18F-Fibroblast Activation Protein Inhibitor (18F-FAPI-74 PET/CT Imaging)
Not yet recruiting·National Heart, Lung, and Blood Institute (NHLBI)·Phase 3·NCT07613099·210 enrolled
Page 1 of 6
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)